

Bellerophon Therapeutics, Inc.  
Form 8-K  
September 27, 2018

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 24, 2018

Bellerophon Therapeutics, Inc.  
(Exact Name of Registrant as Specified in Charter)  
Delaware 001-36845 47-3116175  
(State or Other Jurisdiction of Incorporation) (Commission (IRS Employer  
File Number) Identification No.)

184 Liberty Corner Road, Suite 302 07059  
Warren, New Jersey  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (908) 574-4770

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 24<sup>th</sup>, 2018, Deborah A. Quinn, M.D., the Chief Medical Officer of Bellerophon Therapeutics, Inc. (the “Company”), notified the Company of her intention to resign from her position as Chief Medical Officer effective October 26<sup>th</sup>, 2018.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BELLEROPHON  
THERAPEUTICS, INC.

Date: September 27, 2018    By: /s/ Fabian Tenenbaum  
Name: Fabian Tenenbaum  
Title: Chief Executive Officer